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Summary.-A statistical model has been proposed in an attempt to integrate co-
incidental (or synchronous) diagnoses of multiple primary cancers into a general
method of analysis. In the context of population-based surveys, such diagnoses form
an integral part of the pattern of incidence within the population. Because of clinical
surveillance, the diagnosis of subsequent tumours may be advanced in time in com-
parison with a first primary diagnosis. The model has been used to predict the altered
pattern of diagnosis in order to adjust the value of expected numbers. Data from a
previously reported survey of bilateral breast cancer have been used to illustrate the
model.
Analysis in terms of the model showed a 296-fold increase in risk for a second
primary tumour in the contralateral breast in a series of nearly 22,000 breast-cancer
patients. The corresponding risks for 3 main age-ranges (at the time of diagnosis of
the first primary) were 5-3 (ages 15-44),3-3 (45-59) and 1-5 (60+). In addition, a maxi-
mal risk of 5-0-fold was observed in the series as a whole during the third year after
the diagnosis of the first primary.
IN A PREVIOUS REPORT (Prior & Water-
house, 1978) the incidence of second
primary tumours in the contralateral
breast was evaluated for a series of nearly
22,000 breast-cancer patients registered at
the Birmingham Regional Cancer Registry
over a period of 28 years. Two methods of
assessment were described: Method 1,
which included all coincidental (or syn-
chronous) diagnoses in the observed
number of tumours, showed a 3-fold in-
crease in risk of a second primary; when
coincidental diagnoses were excluded from
the analysis (Method 2) the relative risk
was found to be 2-4 times that of the
general population for a first primary.
The small difference in overall risk
between the two methods might not be of
immediate clinical importance. Neverthe-
less, the cluster of coincidental tumours
(23% of total observed in the series) could
be of aetiological significance, and it also
presented a statistical problem.
Points of difference can be found in the
literature in both the definition and statis-
tical treatment of coincidental tumour.
They have been described variously as
tumours diagnosed (i) during admission
for the first primary or (ii) within varying
intervals from the first primary, namely,
1, 6 or 12 months. For statistical purposes
they have been: (i) included in the analysis
(Robbins & Berg, 1974); (ii) included on an
arbitrary basis (Berg, 1967); (iii) assessed
separately and excluded from the final
comparisons between observed and expec-
ted numbers (Schottenfeld & Berg, 1971;
Veronesi et al., 1974); (iv) eliminated auto-
matically with all other cases diagnosed
within 5 years of the first primary (Green-
berg, 1963; Schoenberg et al., 1969); and
(v) deliberately excluded (Schoenberg &
Christine, 1974) on the grounds that it was
impossible to calculate an expected num-
ber for this group. These differing ap-
proaches to coincidental tumours, inP. PRIOR AND J. A. H. WATERHOUSE
addition to invalidating comparisons be-
tween surveys, suggest that there is some
debate concerning the validity of their
inclusion in an analysis.
For the purposes of the Birmingham
Survey, coincidental tumours were defined
as those diagnosed at the same time as or
within one month ofthe first primary. The
effect of their inclusion and exclusion on
the statistical analysis has been explored.
It was considered, however, that Method
1, on the one hand, although implicitly
acknowledging that coincidental tumours
formed a valid part of the observed num-
ber, made no allowance for their differing
pattern of presentation from that of first
primaries; on the other hand, Method 2
might underestimate the true incidence of
second primary tumours. A third method
is therefore presented here in an attempt
to resolve the statistical dilemma. Al-
though the method was developed pri-
marily within the context of the bilateral
breast survey, the intention was that it
should be of general applicability to
analyses for any pair ofsites. The rationale
for this methodological approach is that,
when population-based Registry data are
used, coincidental tumours, which are all
new diagnoses, form an integral part ofthe
pattern oftumour incidence.
METHOD
Theoretical basis.-The conventional ap-
proach to analysis (Method 1) is based on a
null hypothesis that the diagnoses offirst and
second primary tumours are independent
events. On this basis, incidence rates for first
primaries are used to compute the expected
number of second primary tumours, the
implication being that the pattern ofdevelop-
ment and diagnosis is the same for both
tumours.
A representation of the development of a
first primary in breast is given in Fig. 1:
following the malignant change at A, the
tumour would be detectable but non-
symptomatic at B, symptomatic at C and
would come to clinical diagnosis at D, a point
in time which is determined by the patient
herself seeking medical aid.
Tumour incidence rates are, therefore,
based on "patient-dependent" diagnoses. In
contrast, second primary diagnoses may well
be "clinician-dependent"; when the patient
presents with a first primary, examination
may discover a second primary in its pre-
clinical phase, which in the absence of the
first primary would have been diagnosed
perhaps several months later. Tumours dis-
covered in this way are then the result of
anticipatory diagnosis, which operates when-
ever the patients are under close clinical
supervision. Once patients are discharged
from hospital, or perhaps fail to keep regular
appointments, diagnosis of a subsequent
tumour reverts to the "patient-dependent"
pattern.
The method was developed, therefore, to
recompute the expected number of second
primary tumours on the basis of a predicted
time of diagnosis, which allowed for the
anticipatory effect, in contrast to the con-
ventional method, which assumed complete
independence between the tumours.
The effects of anticipatory diagnosis.-
(i) The maximum yield of second primary
tumours will be obtained when the patient
presents with the first primary (assuming a
detailed examination of every patient). The
number of tumours so found will be de-
pendent on the duration of the preclinical
period.
(ii) Anticipatory diagnosis produces an
apparent deficit of tumours later in the
period of observation. In the simplest situ-
ation, for instance, ifall tumours expected to
occur during the first year were diagnosed
coincidentally, in the absence of any further
clinical follow-up, no more tumours would
present until the second vear.
(iii) Anticipatory diagnosis leads to an
increase in the absolute number of observed
second primaries, an effect which is due to
mortality from the first primaries. If, for
example, conventional analysis gave an
expectation of 100 tumours which increased
to 115 on recomputation, the implication
would be that in the absence of repeated
clinical examinations, 15 patients would have
died with detectable but undiagnosed second
primary tumours.
The increased number oftumours does not,
however, imply an increase in the funda-
mental risk, i.e. the null hypothesis is not
invalidated.
Practical approach.-To recompute the
expected number, typical values were needed
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FIa. 1.-Representation of developmental history for primary tumours.
for (i) duration of the preclinical period and
(ii) the duration of clinical follow-up in order
to make allowance for the effects of antici-
patory diagnosis. An estimated value of 16
months had previously been reported for the
preclinical period (Prior, 1974) and an
arbitrary end point to clinical follow-up
taken at 5 years after first diagnosis. To
visualize the clinical situation and to facilitate
computation, the original model (Fig. 1) was
extended to embrace the clinical histories for
second primary tumours, which are shown in
Fig. 2 for the first 18 months of observation.
The basis of computation was the monthly
unit tumour (NUT) which represents the
yield of tumours in any one month of the
period of observation.
The top line of the model represents the
course of events for all first primary tumours,
B marking the start of the preclinical phase
and D the time of clinical diagnosis. In the
chronology ofthe analysis D is also the origin
(O years 0 months) of the period of clinical
observation for the 2nd primary. Successive
horizontal lines of the model represent co-
horts of second primary tumours which, on
the basis of the null hypothesis, would be
expected to be diagnosed during each month
following the diagnosis of the first primaries.
Each cohort contributes one "expected"
MUT (@) on the line D-D'. The point in
time, in relation to D, when each MUT would
have entered the preclinical phase is indicated
by a corresponding point on the line B-B'
(-). Cohort 1, for instance, would develop
synchronously with the first primaries and
would enter the preclinical phase at -16
months and would be diagnosed at D;
Cohort 5, which would be "expected" to be
diagnosed at 0 years 4 months, would have
entered the preclinical phase at -11 months
and would be diagnosed at D with the first
primaries.
Thus, for all MUT entering the preclinical
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FiG. 2.-Model for predicting the pattern of
diagnosis of coincidental second primary
tumours. MUT status: . preclinical; * clini-
cal, expected; O clinical, predicted.
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period before D, the predicted time of diag-
nosis will be at D, and they are accounted for
in the model by 17 MUT (D-), 16 for the pre-
clinical period and 1 for the first month ofthe
period ofobservation, which is, by definition,
counted as a coincidental tumour.
All that remains to complete the analysis
is to determine the pattern of presentation
of the remaining MUT. If the interval be-
tween follow-up examinations remains less
than the preclinical period, the full comple-
ment of 12 MUT should, theoretically, be
diagnosed each year until the patients are
discharged from further attendance. If all
patients were discharged at the same point in
time, there would be an interval, ofthe order
ofthe duration ofthe preclinical period, when
no further tumours would present, after
which interval the more usual "patient-
dependent" pattern of diagnosis would be
resumed. In practice no such hiatus occurs
because, for several reasons, the reversion
from clinician- to patient-dependent diag-
nosis is a gradual process which decreases the
preclinical period. The result is that fewer
than 12 IIUT are diagnosed in each succeed-
ing year. Taking an end-point of 5 years for
clinical examination, a total of 60 MUT
would be "expected" during the period, 17 of
which would be diagnosed at D, leaving 43
to be distributed over the next 5 years.
In Fig. 3 the model has been extended to
cover the first 5 years of observation. Again,
B-B' delineates the preclinical period for
successive cohorts and D-D' the "expected"
pattern of clinical diagnosis (individual MUT
have not been indicated). As the effect of
B D
2nd. PRIMARY
MUHCOHORR 12[ \\
YEARS from lst. PRIMARY DIAGNOSIS
FIG. 3. Pattern of diagnosis of subsequent
second primary tumours during the first
5 years of observation. MUT status:
..... preclinical; - -- clinical, expected.
clinical, predicted.
anticipatory diagnosis declines, the predicted
point of diagnosis will move from B-B' to
D-D'. In the first instance a linear course,
as depicted in the model, was investigated
which yielded equal numbers of MUT/year
(8.6).
The absolute value ofeach unit depends on
the year of diagnosis, and on the number of
women at risk at that point in time. For
example, if the MUT of Cohort 18 had an
expected diagnosis in Year 2 but was, as the
result of the anticipatory effect, diagnosed in
Year 1, its absolute value would increase from
1-69 to 2-26 tumours because of the greater
number ofwomen alive in the first year. Thus,
the value of the MUT for any one year was
evaluated as:
MUT= 1I x (patient-years at risk x age-
specific incidence rate).
For MUT diagnosed coincidentally with the
first primaries:
MUT= 1 x (number ofpatients x age- 12 specific incidence rate).
For a preclinical period >12 months, such
as was found for breast, an additional value
must be computed substituting (age+1) in
the above equation.
RESULTS
Age atfirst primary diagnosis
The result of the analysis in terms of
age at first primary is given in Table I,
and it can be compared with those for
Method 1 (Table I) and Method 2 (Table
III) in the previous report (Prior & Water-
house, 1978).
Analysis in terms of the model showed
that there was a highly significant (P<
0 001) excess of second primary tumours
for all patients diagnosed with a first
primary before the age of 60. Between
the ages of 60 and 74 the level of signifi-
cance was more variable. After the age of
75 the observed number (22) was not
significantly different from the expected
number (21-3).
Except for age groups 20-24 and 25-29,
the relative risk is lower at each age than
that obtained with Method 1, although the
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TABLE I.-Relative risk ofa secondprimary
breast tumour in relation to age at first
primary (Method 3)
Age
Group E 0
15-19 0-OOt 0
20-24 0-01 3
25-29 0-15 6
30-34 0-91 9
35-39 4-25 28
40-44 12-51 49
Premeno- 17-83 95
pausal
45-49 19-97 79
50-54 18-32 59
55-59 18-83 52
Perimeno- 57-12 190
pausal
60-64 20-17 33
65-69 19-47 35
70-74 15-56 24
75-79 11-40 10
80-84 6-48 10
85-89 2-58 2
90-94 0 58 0
95+ 0 23 0
Postmeno- 76-47 114
pausal
Total 151-42 399
O/E
300 0
40-0
9-9
6-6
3-9
5-3
4 0
3-2
2-8
3-3
1-6
1-8
1-5
0 9
1l5
0 8
p
RELATIVE RISK
6-01
40* 0
.e
2-0e
'Ir A
* 0
*0 0
0
0
@0
0 *
0 @
0
0
NUMBER of TUMOURS
10b0 80-0
60-0
40-0
**
*
1040
8*0
60
40 1-5 ***
2-6
t 1 patient "at risk".
E =Expected number of second primary tUmours.
O =Observed number of second primary tumours.
* P<005; ** P< 0-01; *** P< 0-001.
level of significance has not altered except
for age group 85-89, which had previously
shown an excess of borderline significance
(P< 0.05).
In terms of the 3 age ranges, relative
risk was shown, again, to decrease with
increasing age at first primary, and
although the values were marginally lower
than those obtained by Method 1, all 3
remained highly significant (P < 0-001).
Interval between diagnoses
Observed numbers oftumours are shown
in Fig. 4, in comparison with expected
numbers predicted from the model. For
coincidental tumours, the expectation was
43-82, where 93 were observed, and for the
whole of the first year the corresponding
values were 63-27 and 146.
Over the first 5 years the pattern of
expectation diverges from the linear effect
shown in Fig. 2 ofthe previous report, and
I
20 ,
.Iu 0 1 2 3 4 5 6 7 8 9
Years from Ist. PRIMARY DIAGNOSIS
FIG. 4. Observed (-) and expected (---)
numbers of second primary breast tumours
and the corresponding relative risk for the
first 9 years of observation (Method 3).
although there is an abrupt rise at Year 6
this is, in fact, matched by a corresponding
rise in the observed number.
In Fig. 4 the relative risk over the
same period is seen to rise to a peak at 3
years after the diagnosis of the first
primary. After 5 years the pattern of
observed and expected numbers was the
same as that given in Method 1.
Comparison of the three methods
Table II compares the results for the
first 5 years of observation; subsequent
years will, of course, remain the same for
each method of analysis. Taking all ages
together, the relative risk computed by
Method 3 lies between the values for
Methods 1 and 2, and is marginally closer
] *q)
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TABLE II.-Comparison of results by
analytical method for the first 5 years of
observation, according to age at first
primary
Age at 1st primary
All
Alethlocl
1 0
E
O/E
2 0
E
O/E
3 0
E
O/E
ages
301
85 26
3.5
212
85 26
2 5
301
104-58
2 9
15-44
71
8 30
8 6
65
8 30
7 8
71
9 30
7 6
45-59
142
30 87
4 6
107
30 87
3.5
142
36 73
3.9
60+
88
46 09
1-9
33
46 09
0 7
88
58 55
1.5
to 2. A similar effect was also observed in
the peri- and post-menopausal groups, but
in the premenopausal group Method 2
gave a higher relative risk of 7-83 in com-
parison with that of 7-63 for Method 3.
A comparison of relative risk over the
whole of the survey period is given in
Table III. Again, Method 3 gives a value
intermediate between Methods 1 and 2,
both overall and for the 3 age ranges. The
final values of 5 3, 3*3 and 1P5 for the pre-,
peri- and post-menopausal groups, respec-
tively, represent a relative risk of 2-6 for
the whole series.
TABLE III. Compariison of results by
analytical methodfor all years of observa-
tion, according to age at first primary
Metlhod
1 0
E
O/E
2 0
E
O/E
3 0
E
OIE
All
ages
399
131 76
3 0
310
131 76
2 4
399
151-42
2 6
15-44
years
95
16 82
5 6
89
16 82
5 29
95
17 83
5.33
45-59
years
190
51 25
3.7
155
51 25
3 0
190
57 11
3.3
60+
years
114
63 69
1*8
66
63 69
1-0
114
76 48
1.5
DISCUSSION
Although the concept of anticipative
diagnosis has been generally recognized in
the literature no numerical allowance has
been made for its effect. On the basis of
the method of analysis presented here, an
increase in the expected number of1499%
was demonstrated. Anticipative diagnosis
has a maximal effect at first primary
diagnosis, when every patient is assu-
med to undergo detailed examination,
but with regular surveillance, a residual
effect operates for several years. If every
patient were to be examined at, say, yearly
intervals that is, an interval less than
the duration of the preclinical period-all
second primaries, would, theoretically, be
discovered in the preclinical phase. In
practice this does not happen, because
either (i) patients are discharged from
hospital attendance for follow-up because
they are considered to be well enough or
perhaps because they may be too old or
infirm to attend, or (ii) the interval be-
tween examinations increases because of
missed or delayed appointments.
We consider that the concept of the
monthly unit tumour (MUT) is apt when
working in the context of numbers of
tumours, and it is useful both in visualiz-
ing the clinical situation and in facilitating
computation by allowing manipulation
within the framework of an existing
method of analysis.
So many factors affect the presentation
of tumours after the first diagnosis that
it has not been possible to substantiate
quantitatively the pattern ofdecline in the
preclinical period. However, after many
simulations with the model, it has been
concluded that the peak in risk at 3 years
is not artefactual (i.e. is not a consequence
ofthe model) and that the linear approach
gives a more acceptable pattern of risk
than, say, a decline oflogarithmic form.
Taking the cut-off point for hospital
attendance at 5 years was a compromise,
because clinical practice and patient
reaction varied widely for follow-up pro-
cedure. Breast, too, poses a special prob-
lem in that the contralateral breast is
easily examined without causing undue
anxiety in the patient, with the result that
surveillance for this site is greater than
that for other possible second primary
sites.
The preclinical period, in this context,
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TABLE IV.-Relative risk in relation to the length of the preclinical period. (Unsmoothed
datafor 6 years of observation.)
Age at 1st primary (years)
15-44
Preclinical period
(months)
160 3.4*
2 1 83
84 7.1
12 6 9 8
167 128
5 9 4 6
10.0 7 8
7 3 7:3
45-59
A
Preclinical period
(months)
16-0 16-7*
26 25
4.5 4.5
57 58
58 59
3.3 3.4
3.3 3.3
25 25
60+
Preclinical period
(months)
16-0 25.1*
19 12
09 1 3
0-9 1-1
22 28
22 28
13 13
* Value obtained from intercepts in the regression analysis (see Part I).
encompassed all detectable but not yet
diagnosed tumours, and the value of 16
months for the duration of the pre-
clinical phase again represents a typical
figure with a wide variation. This value
falls, however, between two published
estimates of 20 months (Hutchison &
Shapiro, 1968) based on mammographic
examination and 10 months (Bross et al.,
1968) which was a hypothetical value
based on the assumption of logarithmic
growth of tumours.
Several hypotheses concerning the level
of risk at first examination were investi-
gated, and an extreme evaluation, assum-
ing an age-differential pattern, is given in
Table IV for comparison with that for a
constant preclinical period. We found,
nevertheless, that for a wide range of
values the apparent peak in risk in the 3rd
year remained. A 5-fold risk at this point
was obtained using a constant value for
the preclinical period.
An aetiological explanation of the peak
is not immediately obvious. If multiple
tumours are the result of the same car-
cinogenic challenge, a lag of 3 years
between their maturation is difficult to
explain. It may be, however, that the
peak is related to an event other than the
induction of the first primary. There is
considerable evidence for multiple trans-
formation of the cells throughout the
breast tissue: in one study (Qualheim,
1957) 54% of breasts removed were found
43
to have multiple foci of malignant trans-
formation, and in another report (Bloom,
1968) the change was considered to be
almost certainly bilateral. This would sug-
gest that not all malignant foci progress to
clinical cancer, either because they are
being held in check by the immune system
or because ofslowgrowth, or, even, because
they may spontaneously regress, but once
one focus has progressed to a critical size
in relation to the state of immune surveil-
lance, it may be that a second focus can
break away from homoeostatic control and
come to diagnosis at an interval from the
first primary.
However, another common point in
time could be diagnosis of (and possibly
treatment to) the first primary, a time
which might again represent a period of
immune stress. A short period of immune
depression has been shown to occur after
major surgery (Cochran et al., 1972) and
radiotherapy also has come under close
scrutiny for the same reason (Bond, 1967).
Although the surgical effect was transitory
(6-22 days) and the effect of radiotherapy
localized, they may be sufficient to allow
already transformed cells to escape from
control and proceed to express their malig-
nant potential. The cause of the peak is
not clear, but it would appear from our
results that its effect on risk is more
pronounced in younger women.
Although the data from the bilateral
breast survey have been used here to
Year from
1st primary
Coincidental
1
2
3
4
5
6
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present the model, the effect of anticipa-
tory diagnosis is a common problem of
many epidemiological investigations in
which clinical intervention for one condi-
tion influences the presentation of a
second. Evaluation ofassociations between
cancer and other diseases or between non-
malignant conditions, for instance, would
require similar adjustments.
The model is, perhaps, only a simple
representation of a complex situation, but
it could be refined if more detailed infor-
mation were available. Nevertheless with
such large numbers some generalization is
acceptable. Use of the model for analyses
ofother site pairs will, it is hoped, provide
further justification for an approach which
allows the use ofall available information,
thus avoiding the need to make arbitrary
exclusions.
The survey of multiple primary malignant
tumours is supported by the Cancer Research
Campaign.
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